Published in final edited form as:

Mol Microbiol. 2013 November ; 90(3): 489–501. doi:10.1111/mmi.12378.

Sphingosine kinase A is a pleiotropic and essential enzyme for *Leishmania* survival and virulence

Ou Zhang^{1,†}, Fong-Fu Hsu², Wei Xu¹, Mattie Pawlowic¹, and Kai Zhang^{1,*}

¹Department of Biological Sciences, Texas Tech University, Lubbock, TX 79409, USA.

²Department of Internal Medicine, Washington University School of Medicine, 660 S. Euclid Ave., Saint Louis, MO 63110, USA.

Summary

Sphingosine kinase is a key enzyme in sphingolipid metabolism, catalysing the conversion of sphingosine or dihydrosphingosine into sphingosine-1-phosphate or dihydrosphingosine-1-phosphate respectively. In mammals, sphingosine-1-phosphate is a powerful signalling molecule regulating cell growth, differentiation, apoptosis and immunity. Functions of sphingosine kinase or sphingosine-1-phosphate in pathogenic protozoans are virtually unknown. While most organisms possess two closely related sphingosine kinases, only one sphingosine kinase homologue (SKa) can be identified in *Leishmania*, which are vector-borne protozoan parasites responsible for leishmaniasis. *Leishmania* SKa is a large, cytoplasmic enzyme capable of phosphorylating both sphingosine and dihydrosphingosine. Remarkably, deletion of SKa leads to catastrophic defects in both the insect stage and mammalian stage of *Leishmania* parasites. Genetic and biochemical analyses demonstrate that proper expression of SKa is essential for *Leishmania* parasites to remove toxic metabolites, to survive stressful conditions, and to cause disease in mice. Therefore, SKa is a pleiotropic enzyme with vital roles throughout the life cycle of *Leishmania*. The essentiality of SKa and its apparent divergence from mammalian counterparts suggests that this enzyme can be selectively targeted to reduce *Leishmania* infection.

Introduction

Trypanosomatid parasites of the genus *Leishmania* cause a spectrum of serious diseases (collectively known as leishmaniasis) infecting 10–12 million people in 88 countries (Cunningham, 2002). During their life cycle, these vector-borne protozoans alternate between flagellated promastigotes which live in the midgut of sandflies and non-flagellated amastigotes which reside in the phagosome of mammalian macrophages. Control of leishmaniasis is hampered by the lack of a safe vaccine, limitations of frontline drugs, and the emergence of drug resistant strains (Santos *et al.*, 2008). To develop better treatments, it is necessary to decipher the molecular strategy utilized by *Leishmania* parasites to thrive under the harsh conditions in sandflies and humans.

Sphingolipids (SLs) and their metabolic intermediates are well-characterized bioactive molecules in mammals with diverse roles in raft formation, signal transduction, cell-to-cell

© 2013 John Wiley & Sons Ltd

*For correspondence. kai.zhang@ttu.edu; Tel. (+1) 806 742 2710 ext 250; Fax (+1) 806 742 2963.

†Present address: Department of Microbiology and Immunology, University of Michigan Medical School, 1150 West Medical Center Drive, 5641 Medical Science II, Ann Arbor, MI 48109, USA.

Supporting information

Additional supporting information may be found in the online version of this article at the publisher's web-site.

recognition, and immune responses (Merrill *et al.*, 1993; Vaux and Korsmeyer, 1999; Kolter *et al.*, 2002; Maceyka *et al.*, 2002). Functions of SL metabolism in *Leishmania* have been probed using gene knockout mutants and their reconstituted strains (add-backs). Previously, a *spt2*⁻ mutant that lacks an essential subunit of serine palmitoyltransferase (SPT) was generated in *Leishmania major* through targeted gene deletion (Zhang *et al.*, 2003; Denny *et al.*, 2004). SPT is responsible for the *de novo* synthesis of sphingoid bases including 3-ketodihydrosphingosine and dihydrosphingosine (DHS) (Denny *et al.*, 2004) (Zhang *et al.*, 2003) (Fig. S1), which are intermediates for the production of high order SLs. Other sphingoid bases such as sphingosine (Sph) can be generated through the degradation of ceramide (Mao and Obeid, 2008) (Fig. S1). *Spt2*⁻ mutant is replicative in culture during the logarithmic phase but loses viability during the stationary phase and fails to differentiate from non-infective procyclics to infective metacyclics (a process known as metacyclogenesis in *Leishmania* (Sacks and Perkins, 1985)) (Zhang *et al.*, 2003). Very similar phenotypes are also displayed by another *L. major* mutant named *spl*⁻ which lacks the enzyme sphingosine-1-phosphate lyase (SPL) (Zhang *et al.*, 2007). SPL catalyses the hydrolysis of phosphorylated sphingoid bases such as sphingosine-1-phosphate (S1P) and dihydrosphingosine-1-phosphate (DHS1P) (Fig. S1). Importantly, supplementation of ethanolamine (EtN) completely reversed the viability and differentiation defects of both *spt2*⁻ and *spl*⁻ promastigotes (Zhang *et al.*, 2007). After being taken up by cells, EtN can be converted into EtN-phosphate (EtN-P, a downstream product of SPL; Fig. S1) and then further utilized to synthesize plasmenylethanolamine (PE), which is an abundant phospholipid in *Leishmania* (Zhang *et al.*, 2003; 2007; Gibellini *et al.*, 2008). Therefore, a main function of sphingoid base synthesis and degradation is to generate EtN-P, a metabolite essential for phospholipid synthesis and metacyclogenesis in *Leishmania* promastigotes (Fig. S1).

Recently, the turnover of high order SLs was explored in *Leishmania* parasites. In *L. major*, a single inositol phosphosphingolipid phospholipase C-like (ISCL) protein is responsible for the degradation of both inositol phosphorylceramide (IPC, the predominant SL in *Leishmania*) and sphingomyelin (an abundant SL in mammals) (Zhang *et al.*, 2009). Null mutants of *ISCL* (*iscl*⁻) grew and differentiated normally as promastigotes but were hypersensitive to acidic pH (Xu *et al.*, 2011). These mutants could not cause disease in either immunocompetent or immunocompromised mice, although they were able to persist at low levels at the site of infection (Xu *et al.*, 2011). Further studies demonstrate that the ability to degrade IPC is important for acid tolerance in promastigotes, and the ability to degrade host-derived sphingomyelin is required for amastigote replication and disease development in mammals (Xu *et al.*, 2011; O. Zhang *et al.*, 2012). A parallel study was performed in another *Leishmania* species, *L. (L.) amazonensis*, and the phenotype of *Laiscl*⁻ mutant mostly mimics that of *L. major iscl*⁻ except that the outcome of *Laiscl*⁻ infection is highly dependent on the genetic background of mice (Pillai *et al.*, 2012). Together, these findings strongly suggest that degradation of high order SLs, especially host-derived sphingomyelin, plays a pivotal role in the proliferation of *Leishmania* in mammals and the manifestation of disease.

In addition to SPT, SPL and sphingomyelinase, another well-studied enzyme in SL metabolism is sphingosine kinase (SK) which converts Sph or DHS into S1P or DHS1P respectively (Maceyka *et al.*, 2002). In organisms as diverse as mammals, fruit fly, *C. elegans* and yeasts, two SK isoforms (SK1 and SK2) are responsible for the phosphorylation of sphingoid bases using ATP as the phosphate donor (Maceyka *et al.*, 2002). Mammalian SK1 and SK2 exhibit overlapping substrate specificity but are not redundant due to different developmental expression, tissue distribution and subcellular localization (Kohama *et al.*, 1998; Liu *et al.*, 2000). For example, SK1 is predominantly cytosolic and can be recruited to the plasma membrane upon stimulation (Pitson *et al.*, 2005; Stahelin *et al.*, 2005), while

SK2 shuttles between the cytoplasm and nucleus (Igarashi *et al.*, 2003; Hait *et al.*, 2009). In mammals, S1P (the product of SK1/SK2) is a potent signalling lipid that regulates a plethora of important cellular processes including proliferation, apoptosis, calcium homeostasis, angiogenesis, platelet formation, cell migration and immune responses (Strub *et al.*, 2010; Pitson, 2011; L. Zhang *et al.*, 2012). S1P mainly exerts its function by interacting with a family of cell surface G protein-coupled receptors ('inside-out signalling') to activate various signalling pathways (Rosen *et al.*, 2009; Strub *et al.*, 2010). S1P can also act as a second messenger by regulating intracellular targets such as histone deacetylases, mitochondrial prohibitin 2, and tumour necrosis factor receptor-associated factor 2 (Xia *et al.*, 2002; Hait *et al.*, 2009; Alvarez *et al.*, 2010; Strub *et al.*, 2011). Due to S1P's role in promoting cell survival and proliferation, human SKs have been developed as therapeutic targets for the treatment of certain cancer and inflammatory disorders (Shida *et al.*, 2008; Karliner, 2009; Edmonds *et al.*, 2011). In *Saccharomyces cerevisiae*, genetic studies suggest that cytoplasmic S1P can suppress cell growth and increase heat tolerance at the same time, although the intracellular targets of S1P in fungi have yet to be determined (Lantermann and Saba, 1998; Kim *et al.*, 2000; Birchwood *et al.*, 2001).

In contrast to the wealth of knowledge on S1P signalling in mammals, functions of SK and S1P have not been explored in parasitic protozoans such as trypanosomatids and apicomplexans, which are evolutionarily divergent from animals and fungi. In this study, we investigated a SK homologue in *L. major* named SKa. Based on our previous findings, SKa should be involved in the conversion of serine to EtN-P (Fig. S1) (Zhang *et al.*, 2007). Since S1P regulates numerous processes in mammals, it is tempting to speculate whether SK/S1P possess any other roles in addition to EtN-P production. Here our genetic and biochemical analyses demonstrate that *Leishmania* SKa is a critically important and pleiotropic enzyme responsible for the detoxification of sphingoid bases (during the replicative log phase) and the regulation of stress response (during the non-replicative stationary phase). In addition, the expression level of SKa needs to be carefully controlled to ensure parasite survival in mice. These findings add new knowledge to the role of SL metabolism in *Leishmania* and may open doors to new anti-protozoan treatments.

Results

Identification and genetic manipulation of SKa in *L. major*

A single candidate SK gene was identified in the *L. major* genome (Tritryp DB system ID: LmjF26.0710) and designated as SKa. Syntenic orthologues of SKa are conserved in other trypanosomatid pathogens including *Leishmania braziliensis*, *Leishmania infantum*, *Leishmania mexicana*, *Trypanosoma brucei* and *Trypanosoma cruzi*. While most organisms contain two SK isoenzymes, only one putative SK can be identified in *Leishmania* spp. and *Trypanosoma* spp. With 935 amino acids, the predicted *L. major* SKa protein is significantly larger than its orthologues in mammals and yeasts (Nagiec *et al.*, 1998; Liu *et al.*, 2002) (Fig. S2). It only shows 22–26% overall identity to human SK1/SK2 but does contain five conserved regions (C1–C5 in Fig. S2) and a diacylglycerol kinase domain (amino acid 343–421, underlined in Fig. S2B) which are evolutionarily conserved in all SKs (Pitson, 2011).

To examine the role of SKa, null mutants were generated in *L. major* through two rounds of targeted gene replacement as previously described (Kapler *et al.*, 1990) (Fig. S3A–C). Southern blot analyses with probes from the 5'-flanking region and the open reading frame confirmed the loss of SKa in two *ska*⁻ clones (#2–1 and 2–3 in Fig. S3F–G). To complement these mutants, a high copy plasmid containing SKa (pXG-SKa) was introduced into *ska*⁻ to generate an episomal add-back *ska*^{-/+} SKa (Fig. S3E and G). As expected, these *ska*^{-/+} SKa cells contained many more copies of SKa open read frame than WT parasites (Fig. S3G). To restore SKa expression to near-WT level, we inserted a HA-tagged SKa into the

genomic locus of *SKa* to generate a chromosomal knockin add-back *ska⁻::HA-SKa* ($\Delta SKa::BSD/\Delta SKa::HA-SKa$), using a previously described approach for allelic replacement in *Leishmania* (Madeira da Silva *et al.*, 2009). Southern blot confirmed that these *ska⁻::HA-SKa* parasites had a single copy *SKa* at the correct locus (in Fig. S3F–G, the *SKa* open reading frame in *ska⁻::HA-SKa* is only detectable after 12 h of exposure).

SKa encodes a functional, cytoplasmic SK

To determine if *SKa* encodes a *bona fide* SK, we performed an *in vitro* activity assay by incubating promastigote lysates with 7-nitro-2-1,3-benzoxadiazol (NBD)-labelled Sph (Billich and Ettmayer, 2004). Following extraction, liquids from both the aqueous phase and organic phase were resolved by thin layer chromatography (TLC) (Fig. S4A and B). As expected, the majority of NBD-S1P was detected in the aqueous phase while the majority of NBD-Sph was retained in the organic phase. Compared with WT parasites, *ska⁻* mutants had a reduced yet still detectable level of SK activity (50~60% of WT-level) towards Sph and DHS (Fig. 1A–C). Notably, the chromosomal knockin add-back *ska⁻::HA-SKa* showed a similar SK level as WT parasites, whereas the episomal add-back *ska⁻/+ SKa* exhibited 3–5 time more activity than WT (Fig. 1A–C), presumably due to increased *SKa* copy number (Fig. S3G). These data suggest that while *SKa* encodes an active enzyme which can phosphorylate both Sph and DHS, it may not be the only SK in *L. major*. In a metabolic labelling experiment, live WT and *ska⁻* promastigotes were incubated with [3-³H]-serine for 48 h and then subjected to lipid analysis by TLC as previously described (Zhang *et al.*, 2007). As shown in Fig. 1D, WT parasites could metabolize serine into PE, PC, IPC and ceramide. In contrast, the incorporation of serine into PE and PC was much less robust in *ska⁻* promastigotes (Fig. 1D). Meanwhile, a significant accumulation of labelled sphingoid base was detected in *ska⁻* mutants and this was largely reversed in the *ska⁻/+ SKa* parasites (Fig. 1D). Collectively, these data suggest that *L. major* possess more than one functional SK, although only *SKa* is recognizable in the genome.

To determine the impact of *SKa* deletion on lipid synthesis, we examined the composition of major phospholipids by mass spectrometry. As indicated in Fig. S5, the lipid profile (PE, PI, IPC and ceramide) was not drastically altered in log phase *ska⁻* parasites. This is likely due to the salvage of phospholipids and SLs from the culture medium which would bypass the sphingoid base metabolism (see the pathway in Fig. S1), similar to the log phase *spt2⁻* and *spl⁻* parasites (Zhang *et al.*, 2007). We also quantified the abundance of plasmenylethanolamine (PLE), which is the dominant type of PE in *Leishmania* (Zhang *et al.*, 2007). As summarized in Table 1, the level of PLE in log phase promastigotes of *ska⁻* was only slightly lower than that in WT or *ska⁻/+ SKa* parasites (not statistically significant).

To determine where *SKa* is expressed in promastigotes (the sandfly stage), a GFP-*SKa* fusion protein was introduced into *L. major* WT parasites (on a high copy-number plasmid) and the transgenic WT/+GFP-*SKa* cells displayed a high level of SK similar to that of *ska⁻/+ SKa* (data not shown), indicating that the GFP-fusion protein was functional. By immunofluorescence microscopy, GFP-*SKa* was primarily found in the cytoplasm (Fig. 2A–D). Similar results were observed when the *ska⁻::HA-SKa* promastigotes were probed with an anti-HA antibody (Fig. S6), indicating that the cytoplasmic localization is not an overexpression artefact. To examine the localization of *SKa* in amastigotes (the mammalian stage), murine macrophages infected with WT/+GFP-*SKa* parasites were subjected to immunofluorescence analysis using an anti-GFP antibody. As illustrated in Fig. 2E–I, a clear cytosolic distribution was detected in intracellular amastigotes. Therefore, *SKa* is mainly expressed in the cytoplasm of *Leishmania* parasites.

Ska⁻ promastigotes manifest severe growth defect due to sphingoid base accumulation

Immediately after obtaining the *ska*⁻ knockout, we noticed that these mutants could only grow to $6-8 \times 10^6$ cells ml⁻¹ in culture, which was only 1/4 to 1/3 of the maximal density for WT promastigotes (Fig. 3A). Afterwards, they gradually died in 3–4 days (Fig. 3A and B). When the viable, log phase *ska*⁻ promastigotes (at $1-5 \times 10^6$ cells ml⁻¹) were inoculated in fresh media at 10^1-10^5 cells ml⁻¹, their growth rates and doubling times were nearly identical to those of WT parasites until culture densities reached $6-8 \times 10^6$ cells ml⁻¹ (Fig. 3A and data not shown). Importantly, reconstitution of SKa expression through either chromosomal knockin (*ska*⁻::*HA-SKa*) or episomal complementation (*ska*⁻/+ *SKa*) fully restored *ska*⁻ survival and proliferation in culture (Fig. 3A and B). Unlike the *spt2*⁻ or *spl*⁻ mutants (Zhang *et al.*, 2007), *ska*⁻ parasites could not be rescued by exogenous EtN alone (Fig. 3C and D), indicating that SKa has additional roles beyond EtN-P production (Fig. S1). Exogenous S1P or DHS1P also failed to rescue *ska*⁻ (Fig. S7), suggesting that the function of SKa is not mediated through membrane-bound receptors that recognize S1P or DHS1P. This is consistent with the lack of G-protein coupled receptors in *Leishmania* genome (Ivens *et al.*, 2005).

The rapid demise of *ska*⁻ after reaching $6-8 \times 10^6$ cells ml⁻¹ suggests that certain toxic metabolites are secreted by the mutant or released from dead parasites. Indeed, conditioned medium from dying *ska*⁻ culture was deleterious to WT promastigotes ('c' in Fig. S8). In contrast, conditioned medium from healthy, low-density *ska*⁻ culture could support parasite growth ('a' and 'b' in Fig. S8). Being the substrates of SK, sphingoid bases such as DHS and Sph are known to exert surfactant effect (as membrane disruptors) in mammalian cells (Contreras *et al.*, 2006). They are also potent inhibitors of protein kinase C (Hannun *et al.*, 1986; Merrill *et al.*, 1986). In culture, both DHS and Sph exhibited strong anti-proliferation activities (IC₅₀= 1–5 μM) against *L. major*, *L. amazonensis*, *L. mexicana*, and *L. donovani* (Fig. S9A–D and data not shown). By comparison, ceramides were not nearly as toxic (IC₅₀ > 14 μM) (Fig. S9E and F). These findings, along with the lack of ceramide accumulation in *ska*⁻ (Fig. 1D and Fig. S5), suggest that ceramides are unlikely to be the toxic metabolites.

To examine whether *ska*⁻ died from sphingoid base accumulation, myriocin (MYR) was added to promastigote medium to block the *de novo* SL synthesis (Fig. S1) (Zhang *et al.*, 2003). EtN was also provided to ensure EtN-P production (Fig. S1) (Zhang *et al.*, 2007). Remarkably, the combination of MYR (1–10 μM) and EtN (100–500 μM) completely restored the viability, morphology, and proliferation rate of *ska*⁻ (Fig. 3C and D; Fig. 4A and B) in culture. In addition, these chemically rescued mutants (*ska*⁻ + MYR + EtN) produced similar amounts of metacyclics as WT, *ska*⁻::*HA-SKa* and *ska*⁻/+ *SKa* parasites in stationary phase (Fig. 4A). Without EtN, MYR alone partially rescued the growth and survival of *ska*⁻ but not metacyclogenesis (Fig. 4A and B), which was similar to the *spt2*⁻ mutant and in agreement with our previous finding that EtN-P production is required for differentiation (Zhang *et al.*, 2007). Based on these findings, we conclude that a crucial role of SKa in *Leishmania* promastigotes is to avert the accumulation of toxic sphingoid bases (Fig. S1). The fact that *ska*⁻ mutants still possess significant SK activity (Fig. 1) suggests that even a partial inhibition of SK can be detrimental to *Leishmania*. Unless otherwise specified, MYR (1 μM) and EtN (200 μM) were provided to *ska*⁻ promastigote cultures in all the studies described below.

Ska⁻ promastigotes are extremely vulnerable to stress

To establish infection and proliferate in the mammalian host, *Leishmania* parasites must develop resistance to various stress conditions including elevated temperature, acidic pH and increased concentration of reactive oxygen species/reactive nitrogen species. To investigate if SKa was required for thermotolerance, *L. major* promastigotes were cultured to stationary

phase at 27°C (the regular temperature for promastigotes) and then exposed to higher temperatures (33°C or 37°C). As illustrated in Fig. 5A, the majority of *ska*⁻ mutants (55–74%) lost viability at 37°C in 24 h, whereas WT, *ska*^{-::HA-SKa} and *ska*^{-/+ SKa} parasites were mostly alive (only 14–22% death). Meanwhile, *ska*⁻ mutants survived much better after exposure to 33°C (Fig. 5A). To test whether SKa was involved in acid resistance, stationary phase promastigotes were transferred from a neutral medium (pH 7.4, the regular pH for promastigote medium) to an acidic medium (pH 5.0). Significantly, *ska*⁻ mutants failed to adapt and 66–73% of them died within 24 h (Fig. 5B). In contrast, only 4–12% of WT and *ska*^{-/+ SKa} cells were dead following the same treatment (Fig. 5B). We also evaluated the ability of *ska*⁻ mutants to survive oxidative and nitrosative stress. As shown in Fig. 5C and D, these knockout parasites were hypersensitive to *S*-nitroso-*N*-acetylpenicillamine (a nitric oxide releaser) and hydrogen peroxide. Therefore, although *ska*⁻ mutants supplemented with MYR and EtN could replicate and differentiate normally in culture, they were highly susceptible to stress.

As a control, WT promastigotes grown in the presence of MYR and EtN did not exhibit any significant difference in those tests (Fig. S10), indicating that the stress response defect of *ska*⁻ is not caused by MYR and EtN (Fig. 5). In addition, exogenous sphingoid bases or ceramides had little effect on WT parasites in stress response (Fig. S10). Together, these findings suggest that it is the production of S1P (not the accumulation of sphingoid base) that is crucial for *Leishmania* to adapt to conditions in the mammalian host.

Surface virulence factors in *Leishmania* including lipophosphoglycan (LPG) and glycoprotein 63 (GP63) are known to confer resistance to oxidants, complements, and alter host signalling pathways (Spath *et al.*, 2003; Gomez *et al.*, 2009). To examine whether SKa played a role in the synthesis of GPI-anchored molecules, promastigote lysates were subjected to Western-blot analysis using antibodies against LPG and GP63. As illustrated in Fig. S11, cellular levels of LPG and GP63 in *ska*⁻ and *ska*^{-/+ SKa} were comparable to those in WT parasites, suggesting that deletion or overexpression of *SKa* had no adverse effect on the expression of GPI-anchored surface virulence molecules.

***Ska*⁻ and *ska*^{-/+ SKa} parasites fail to cause disease in susceptible mice while the *ska*^{-::HA-SKa} parasites are fully infective**

The impact of SKa on *L. major* virulence was evaluated by macrophage infection and footpad infection of susceptible BALB/c mice. As shown in Fig. 6A and B, stationary phase *ska*⁻ promastigotes (complemented with MYR + EtN) were able to invade and survive in murine macrophages (derived from the bone marrow of BALB/c mice) at a similar level as WT and *ska*^{-/+ SKa} parasites. Apparently, *ska*⁻'s deficiency in stress response (summarized in Fig. 5) does not affect their ability to parasitize macrophages in this short *in vitro* assay (3–4 days).

However, these *ska*⁻ mutants (stationary phase promastigotes) failed to generate any pathology in BALB/c mice (after 20 weeks), which were highly susceptible to WT infection (Fig. 7A). Curiously, although the *ska*^{-/+ SKa} parasites (the episomal add-back) were completely normal as promastigotes in culture, they did not reverse the virulence defect of *ska*⁻ (Fig. 7A). Only the *ska*^{-::HA-SKa} cells (the chromosomal knockin add-back) induced progressive footpad lesions (similar to WT) which correlated with the increasing number of parasites (Fig. 7A and B). Very similar results were obtained when mice were infected with purified metacyclics of WT, *ska*⁻ or *ska*^{-/+ SKa} (Fig. S12A). Despite their lack of virulence, both *ska*⁻ and *ska*^{-/+ SKa} parasites were able to persist at low levels in mice (1–600 parasites/footpad) (Fig. 7B and Fig. S12B). Finally, parasites recovered from *ska*^{-/+ SKa}-infected mice (after 5–20 weeks) still contained the pXG-*SKa* episome (data not shown), ruling out the possibility of plasmid loss. The fact that only the chromosomal knockin add-

back restores virulence suggests that in order to be functional during the mammalian stage, SKa must be expressed at near-WT level and/or from its endogenous locus.

Discussion

Previous studies of the *spt2*⁻ and *spt1*⁻ mutants demonstrate that a major role of sphingoid base metabolism in *Leishmania* is to provide EtN-P, which is probably used to synthesize PE and PC (Zhang *et al.*, 2007). Here we investigated the function of SK in *Leishmania* using reverse genetic approaches. SKs are conserved lipid kinases catalysing a key step in SL metabolism, i.e. the formation of S1P or DHS1P from Sph or DHS (Fig. S1). While most organisms possess two closely related SK isoforms, only one SK homologue (SKa) can be identified in *Leishmania* genome. Overexpression of SKa in *L. major* led to increased SK activity but no obvious defects in culture. SKa-null mutants (*ska*⁻) showed reduced SK activity but could still metabolize serine into downstream products including ceramide, IPC, PE and PC (Fig. 1). Remarkably, this partial block of SK activity was sufficient to cause a devastating consequence to *ska*⁻ promastigotes, as these mutants only grew to 1/4 to 1/3 of WT-level in culture and then died in 3–4 days (Figs 3 and 4). Further studies indicate that this catastrophic defect was likely due to the accumulation and release of toxic sphingoid bases generated from *de novo* synthesis (Figs 3 and 4; Figs S7–S9). To alleviate this problem, MYR and EtN were supplemented to *ska*⁻ to inhibit sphingoid base synthesis without compromising EtN-P production. Our results suggest that during the replicative log phase, *Leishmania* promastigotes must maintain a robust level of SKa to: (i) fulfil the need for EtN-P production and phospholipid synthesis; and (ii) eliminate free sphingoid bases to avoid cytotoxicity.

Besides detoxification, SKa also plays an important role in the stress response of non-replicative, stationary phase promastigotes. While *ska*⁻ promastigotes supplemented with MYR + EtN replicated and differentiated normally in culture, they were hypersensitive to heat, acidic pH, oxidants and nitrosative stress (Fig. 5). These defects are not caused by the accumulation of MYR, EtN, sphingoid bases, or ceramides (Fig. S10). Therefore, in addition to being intermediates for EtN-P production, S1P or DHS1P may act as central regulators controlling the transition of *Leishmania* from insect stage to mammalian stage. In mammals, S1P exerts its function by binding to cell membrane receptors or intracellular targets. The cytoplasmic localization of SKa (in both promastigotes and amastigotes) suggests that the target of S1P/DHS1P in *Leishmania* is cytosolic, which is consistent with the lack of G-protein coupled membrane receptors in the annotated genomes of trypanosomatids. It is worth mentioning that the *spt2*⁻ mutants or WT parasites grown in the presence of MYR (defective in the *de novo* synthesis of sphingoid bases) did not exhibit any deficiency in resistance to heat, acidic pH, or oxidative/nitrosative stress when grown in the presence of EtN (data not shown). These findings suggest that *Leishmania* parasites can salvage sufficient amount of sphingoid bases to satisfy the need for S1P or DHS1P in stress tolerance. Alternatively, SKa protein may possess a secondary function that is vital for stress response yet independent of SK activity, which may explain its significant sequence divergence from other SKs (Fig. S2). Future studies will attempt to identify the proteins that bind SKa and/or its products (S1P/DHS1P), which may lead to new light on the role of sphingolipid metabolites in a protozoan parasite.

Although the *ska*⁻ mutants (when supplemented with MYR + EtN) could invade murine macrophages and survive well for 3–4 days *in vitro*, they completely failed to proliferate or cause disease in BALB/c mice (Figs 6 and 7). Such a severe virulence defect is in line with their inability to adapt to mammalian conditions. While the accumulation of sphingoid bases in *ska*⁻ is clearly detrimental to promastigotes, it is unlikely to be a major factor during the mammalian stage because the *de novo* synthesis of sphingoid base is greatly downregulated

in amastigotes (which acquire EtN through salvage) (Zhang *et al.*, 2005; 2007). Interestingly, only the chromosomal knockin add-back displayed WT-level infectivity while the episomal add-back failed to produce any pathology in mice (Fig. 7), despite the fact that both add-back parasites showed WT-like phenotypes in culture, e.g. in growth and stress response. It is possible that the flanking sequences of *SKa* open reading frame play a crucial role in the post-transcriptional regulation of *SKa* during the amastigote stage, such as ensuring mRNA stability and translation efficiency. This type of gene expression control is not uncommon among trypanosomatids (McNicoll *et al.*, 2005; Haile *et al.*, 2008) and may explain why *SKa* must be at its endogenous locus to be fully functional. Alternatively, the over expression of *SKa* may have deleterious consequences in the episomal add-back parasites during the amastigote stage (although it is well tolerated by promastigotes). In mammals, the synthesis of S1P is tightly regulated both spatially and temporally to limit any potential adverse effects from this powerful signalling molecule (Strub *et al.*, 2010; Pitson, 2011; Siow *et al.*, 2011). Further studies will shed light on the regulation and target(s) of *SKa*, which should expand our current knowledge on sphingoid metabolism in non-mammalian systems.

In summary, *SKa* is an extraordinarily important enzyme in both the promastigote stage and amastigote stage of *Leishmania* because: (i) a robust level of *SKa* is necessary to remove toxic sphingoid base from replicating promastigotes which have a high demand for EtN-P; (ii) *SKa* is also required the non-replicating promastigotes to survive elevated temperature, acidic pH and increased concentrations of reactive oxygen intermediates/reactive nitrogen intermediates; and (iii) the expression of *SKa* must be carefully regulated during the mammalian stage to ensure amastigote proliferation and disease progression. Since *SKa* is only marginally related to human SKs, it is tempting to consider its potential as a drug target. While even a partial inhibition of SK is detrimental to *Leishmania*, genetic deletion of either SK1 or SK2 leads to no obvious defects in mice and only the double knockout is lethal (Mizugishi *et al.*, 2005). Therefore, mammals may be more tolerant to SK inhibitors than *Leishmania*. It is also of note that human SKs have been explored as targets for immunomodulatory drugs (e.g. FTY720) and anti-tumour drugs (Shida *et al.*, 2008; Pitman and Pitson, 2010; Pyne and Pyne, 2011; Raje *et al.*, 2012), using fluorescence-based, high throughput SK assays that are commercially available. In the future, to evaluate its potential as a new anti-*Leishmania* target, it is necessary to purify recombinant *SKa*. Although *SKa* is predicted to be a large protein (101 kDa), the lack of transmembrane domains and its cytoplasmic localization suggest the recombinant enzyme can be soluble.

Given the importance of *SKa*, future studies will also focus on other enzymes involved in the dynamics of sphingoid bases and S1P. For instance, the phenotype of *ska*⁻ mutants suggests that although a second SK exists in *Leishmania*, it is not sufficient to detoxify sphingoid bases or control stress response when it is expressed at the endogenous level. While most organisms (including human, slime mould, worms, fruit fly and yeast) possess two isoforms of SK that share a high degree of sequence similarity (Hait *et al.*, 2006), the second SK cannot be readily identified in the genomes trypanosomatid parasites. Future investigations may reveal why these protozoans produce two highly divergent SKs in the context of enzymatic specificity, parasite physiology and evolution. Another enzyme of interest would be the S1P phosphatase which catalyses the degradation of S1P. Along with the S1P lyase (SPL), S1P phosphatase counters the activity of SK by reducing S1P level therefore controls the cellular concentrations of sphingoid bases and their phosphorylated products. Characterization of enzymes involved in sphingoid base metabolism would improve our understanding on *Leishmania* biology and expand our knowledge on SL-mediated signalling.

Experimental procedures

Ethics statement for mouse use

The use of mice in this study was approved by the Animal Care and Use Committee at Texas Tech University (US PHS Approved Animal Welfare Assurance NO. A3629-01). BALB/c mice (female, 7–8 weeks old) were purchased from Charles River Laboratories International. Mice were housed and cared for in the facility operated by the Animal Care and Resources Center at Texas Tech University adhering to the *Guide for the Care and Use of Laboratory Animals* (the 8th Edition, NRC 2011) for animal husbandry. The facility was inspected monthly and animals were monitored daily by staff members. A complete range of clinical veterinary services was available on a 24 h basis including consultation, diagnostic work-up and clinical care. Lab personnel participating in this study are trained to use proper restraining and injection techniques to reduce pain and distress of animals without compromising the quality of research. Mice were anesthetized (through the intraperitoneal injection of 100 mg kg⁻¹ of ketamine hydrochloride and 10 mg kg⁻¹ of xylazine) prior to the injection of *Leishmania* parasites into footpads, the recovery of parasites from infected mice, and the measurement of lesion size using a caliper. Usually, no more than one procedure was performed on any mouse within a week. Mice were monitored twice a week for appearance, size, movement and general health condition. Mice were euthanized by carbon dioxide asphyxiation when footpad lesions became over 2.5 mm or when secondary infection was detected. Mice were also euthanized prior to the isolation of femur cells and limiting dilution assay (to determine parasite load in infected tissue).

Materials

Omega(7-nitro-2-1,3-benzoxadiazol-4-yl) (2S,3R,4E)-2-amino-octadec-4-ene-1,3-diol (C18 NBD-sphingosine) and omega(7-nitro-2-1,3-benzoxadiazol-4-yl) (2S,3R)-2-amino-octadecane-1,3-diol (C18 NBD-dihydrosphingosine) were purchased from Avanti Polar Lipids (Birmingham, AL). Human recombinant SK2 and ATP were purchased from Sigma-Aldrich. L-[3-³H(G)]-serine (23Ci mmol⁻¹) was purchased from Perkin Elmers. All other chemicals were purchased from VWR International or Fisher Scientifics unless specified otherwise.

Molecular constructs

The open reading frame (ORF) of *SKa* (LmjF26.0710) was amplified by PCR from *L. major* genomic DNA using primers P207 (attactggatccaccATGCACTCTCTCAGCTCC) and P210 (attactggatccCTACCCACTGCGCACGAAGT). The resulting 2.8 kb DNA fragment was digested with BamHI and cloned into the pXG vector (Ha *et al.*, 1996) as pXG-*SKa* (B195). After confirming its sequence, the *SKa* ORF was subcloned into the pXG-GFP+2' vector (Ha *et al.*, 1996) to generate pXG-GFP-*SKa* (B285), which was used in localization studies. To generate *SKa* knock-out constructs, the predicted 5'- and 3'-flanking sequences (~ 800 bp each) were PCR amplified and cloned in tandem into the pUC18 vector. Genes conferring resistance to puromycin (*PAC*) and blasticidin (*BSD*) were then inserted between the 5'- and 3'-flanking sequences to generate pUC-KO-*SKa:PAC* (B225) and pUC-KO-*SKa:BSD* (B224) respectively. In addition, a HA-tagged *SKa* ORF and its 5'-flanking sequence were cloned into the pGEM-phleo-HA' (B202) vector (Madeira da Silva *et al.*, 2009) to generate pGEM-5'UTR-phleo-HA-*SKa* (B289). This construct was used to express *SKa* from its chromosomal locus (Madeira da Silva *et al.*, 2009).

Leishmania culture and genetic manipulations

Leishmania major FV1 (MHOM/IL/81/Friedlin) wild type (WT) promastigotes were grown in M199 medium with 10% fetal bovine serum (FBS) and other supplements as previously

described (Kapler *et al.*, 1990). Unless specified otherwise, *ska*⁻ mutants were grown in the presence of 1 μ M of MYR and 200 μ M of EtN. Treatment with MYR and EtN had no detectable effect on the proliferation, differentiation, or infectivity of WT parasites (data not shown). Promastigote replication was determined by monitoring culture density over time using a haemocytometer. Cell viability was examined by flow cytometry (using an Accuri C6 flow cytometer) after staining with 5 μ g ml⁻¹ of propidium iodide. Metacyclics were isolated from the stationary phase culture by the density gradient centrifugation method (Spath and Beverley, 2001) or the peanut agglutination method (Sacks *et al.*, 1985). The two *SKa* alleles in WT parasites were sequentially replaced by *PAC* and *BSD* resistance genes to generate the *ska*⁻ mutant ($\Delta SKa::PAC/\Delta SKa::BSD$). Transfection and selection of drug-resistant promastigotes were performed as previously described (Kapler *et al.*, 1990). To confirm *SKa* deletion in *ska*⁻, genomic DNA was digested with *ScaI*, resolved on a 0.7% agarose gel, transferred to a nitrocellulose membrane, and hybridized with a ³²P-labelled DNA probe corresponding to either the *SKa* ORF or the 5'-flanking sequence. To restore *SKa* expression via episomal overexpression, pXG-*SKa* was transfected into the mutant and the resulting add-back parasite (resistant to G418) was referred to as *ska*^{-/+} *SKa* ($\Delta SKa::BSD/\Delta SKa::PAC$ + pXG-*SKa*). To restore *SKa* expression to near WT-level, we generated a *SKa* chromosomal knockin by integrating a HA-tagged *SKa* ORF into the genomic locus of *SKa* as previously described (Madeira da Silva *et al.*, 2009). To do so, the plasmid DNA of pGEM-5'UTR-phleo-HA-*SKa* was linearized with *EcoRI* and introduced into the *SKa* heterozygote parasites ($\Delta SKa::BSD/ SKa$); cells showing resistance to blasticidin and phleomycin were selected; finally, these knockin parasites were confirmed by Southern-blot and designated as *ska*^{-::HA-SKa} ($\Delta SKa::BSD/\Delta SKa::HA-SKa$). To study *SKa* localization, pXG-GFP-*SKa* was transfected into WT parasites to generate WT/+ GFP-*SKa* parasites (resistant to G418).

SK activity assay

Log phase promastigotes (1–4 $\times$ 10⁶ cells ml⁻¹ in culture) were resuspended in a lysis buffer (50 mM HEPES pH 7.4, 800 mM KCl, 2 mM dithiothreitol, 2 mM ATP, 0.02% Triton X-100, 20 mM MgCl₂, 20 mM NaF and 2 $\times$ protease inhibitor cocktail) at 4.0 $\times$ 10⁸ cells ml⁻¹ and incubated on ice for 5 min. Protein concentration was determined by the BCA assay (Pierce). SK assay was performed as previously described with minor modifications (Billich and Ettmayer, 2004). Briefly, C18 NBD-Sph or C18 NBD-DHS was prepared in 4 mg ml⁻¹ low fat bovine serum albumin at a final concentration of 30 μ M. Each assay reaction contained 25 μ l of *Leishmania* cell lysate (~40 μ g of total protein) and an equal volume of C18 NBD-Sph or C18 NBD-DHS. After 30 min incubation at 27°C, the reaction was terminated by adding 50 μ l of K₂HPO₄ (1 M, pH 8.5) and 250 μ l of chloroform : methanol (2:1). After centrifugation (13 000 g, 2 min), the upper aqueous phase (containing NBD-labelled S-1-P or DHS-1-P) was separated from the lower organic phase (containing NBD-labelled substrates). Fractions of upper phase and lower phase were loaded separately on aluminum-backed silica gel plates (Sigma-Aldrich). NBD-labelled products/substrates were separated by thin layer chromatography (solvent: chloroform/methanol/ammonium hydroxide = 10/10/3) and detected with a Storm 860 phosphorimager. 0.1 unit of recombinant human SK2 was used as a positive control and boiled WT lysate (~40 μ g of total protein) was used as a negative control. SK activity [nmol (μ g $\times$ h)⁻¹] was calculated based on the amount of NBD S1P or NBD DHS1P produced in each reaction after subtracting the value of negative control.

Metabolic labelling with[3-³H]-serine

Promastigotes were inoculated at 1.0 $\times$ 10⁵ cells ml⁻¹ and labelled with 1.5 μ Ci ml⁻¹ of L-[3-³H(G)]-serine. After 48 h, parasites were harvested and total lipids (from ~1 $\times$ 10⁸ cells)

were extracted using the Bligh-Dyer method (Bligh and Dyer, 1959). TLC was performed as previously described (Zhang *et al.*, 2007).

Lipid analysis by electrospray ionization mass spectrometry(ESI-MS)

Lipid extraction and analysis by ESI-MS (negative ion mode) were performed similarly as previously described (Zhang *et al.*, 2007). A 1-*O*-1'-(*Z*)-octadecenyl-2-arachidoyl-*sn*-glycero-3-phosphoethanolamine (*p*18:0/20:4-PE, FW = 751.6, Avanti Polar Lipids) was used as a standard to quantify PLE. This standard was added to cell lysates prior to lipid extraction (at 1.0×10^8 molecules per cell).

Immunofluorescence microscopy

To determine the localization of SKa in promastigotes, log phase parasites of WT/ + *GFP-SKa* or *ska⁻::HA-SKa* were fixed in 3.7% formaldehyde, attached to poly-L-lysine coated coverslips, and permeabilized with 0.5% Triton X-100 (prepared in PBS) at room temperature for 15 min. Immunofluorescence microscopy was performed as previously described (Zhang *et al.*, 2003). Primary antibody: rabbit anti-GFP polyclonal antibody (1:1000, Life Technologies) or rabbit anti-HA polyclonal antibody (1:50, Life Technologies). Secondary antibody: goat anti-rabbit IgG-Texas Red (1:1000, Life Technologies).

To determine the localization of SKa in amastigotes, THP-1 derived macrophages were infected with stationary promastigotes (10 parasites per macrophage) and incubated at 37°C/ 5% CO₂ for 48 h. Macrophages were then fixed in 3.7% formaldehyde and permeabilized with ice-cold ethanol for 15 min. Immunofluorescence assay was then performed as described above.

Leishmania stress response

Promastigotes were grown in regular medium (M199/10% FBS and supplements, pH 7.4) at 27°C to stationary phase (culture density = $2.0-3.5 \times 10^7$ cells ml⁻¹) and used in the following assays. To test temperature sensitivity, parasites were kept in regular medium and incubated at 27°C, 33°C/5% CO₂, or 37°C/5% CO₂ (Xu *et al.*, 2011). To examine their tolerance to acidic pH, parasites were either kept in regular medium (pH 7.4) or transferred to a pH 5.0 medium (same as the regular medium except the pH was modified with hydrochloric acid) and incubated at 27°C (Xu *et al.*, 2011). To measure their sensitivity toward oxidative and nitrosative stress, parasites were cultured in 24-well plates (regular medium, 27°C) in the presence of 0–500 μM of H₂O₂ or *S*-nitroso-*N*-acetylpenicillamine (SNAP) (Xu *et al.*, 2011). Cell density and viability were determined at the indicated time points.

Murine macrophage (MΦ) infection

Bone marrow-derived MΦs were generated from the femur cells of BALB/c mice in complete DMEM/10% FBS + 20 ng ml⁻¹ macrophage colony-stimulating factor for 4 days at 37°C/5% CO₂. Infection was performed with late stationary phase parasites (opsonized with C57BL6 mouse serum) at a ratio of twenty parasites per one MΦ as previously described (Racoosin and Beverley, 1997). MΦs were then incubated at 33°C/5% CO₂ for 3 days. Percentages of infected MΦs and the number of parasites per 100 MΦs were determined by microscopy after staining with 1 μg ml⁻¹ of Hoechst 33342.

Mouse infections and analyses

Stationary phase promastigotes were inoculated into BALB/c mice ($2-5 \times 10^7$ cells per mouse) and recovered after 3–4 weeks. Virulence of these low passage parasites (*in vitro*

passages < 5) was evaluated by footpad infection as previously described (Titus *et al.*, 1991), using either stationary promastigotes (1×10^6 cells per mouse, 5 mice per group) or purified metacyclics (2×10^5 cells per mouse, 5 mice per group). Footpad lesions were measured weekly using a vernier caliper and parasite numbers were determined by limiting dilution assay (Titus *et al.*, 1985).

Western blot

To determine the expression level of GPI-anchored molecules, promastigotes were harvested and Western blot analyses were performed with antibodies against LPG or GP63 as previously described (Zhang *et al.*, 2004).

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Agiesh Pillai and Neha Kumari for technical assistance and helpful discussions. The rabbit anti-*Leishmania* GP63 was a kind gift from Dr KP Chang (Rosalind Franklin University).

References

- Alvarez SE, Harikumar KB, Hait NC, Allegood J, Strub GM, Kim EY, et al. Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. *Nature*. 2010; 465:1084–1088. [PubMed: 20577214]
- Billich A, Ettmayer P. Fluorescence-based assay of sphingosine kinases. *Anal Biochem*. 2004; 326:114–119. [PubMed: 14769343]
- Birchwood CJ, Saba JD, Dickson RC, Cunningham KW. Calcium influx and signaling in yeast stimulated by intracellular sphingosine 1-phosphate accumulation. *J Biol Chem*. 2001; 276:11712–11718. [PubMed: 11278643]
- Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. *Can J Biochem Physiol*. 1959; 37:911–917. [PubMed: 13671378]
- Contreras FX, Sot J, Alonso A, Goni FM. Sphingosine increases the permeability of model and cell membranes. *Biophys J*. 2006; 90:4085–4092. [PubMed: 16533839]
- Cunningham AC. Parasitic adaptive mechanisms in infection by *Leishmania*. *Exp Mol Pathol*. 2002; 72:132–141. [PubMed: 11890722]
- Denny PW, Goulding D, Ferguson MA, Smith DF. Sphingolipid-free *Leishmania* are defective in membrane trafficking. *Differentiation*. 2004; 52:313–327.
- Edmonds Y, Milstien S, Spiegel S. Development of small-molecule inhibitors of sphingosine-1-phosphate signaling. *Pharmacol Ther*. 2011; 132:352–360. [PubMed: 21906625]
- Gibellini F, Hunter WN, Smith TK. Biochemical characterization of the initial steps of the Kennedy pathway in *Trypanosoma brucei*: the ethanolamine and choline kinases. *Biochem J*. 2008; 415:135–144. [PubMed: 18489261]
- Gomez MA, Contreras I, Halle M, Tremblay ML, McMaster RW, Olivier M. *Leishmania* GP63 alters host signaling through cleavage-activated protein tyrosine phosphatases. *Sci Signal*. 2009; 2:ra58. [PubMed: 19797268]
- Ha DS, Schwarz JK, Turco SJ, Beverley SM. Use of the green fluorescent protein as a marker in transfected *Leishmania*. *Mol Biochem Parasitol*. 1996; 77:57–64. [PubMed: 8784772]
- Haile S, Dupe A, Papadopolou B. Deadenylation-independent stage-specific mRNA degradation in *Leishmania*. *Nucleic Acids Res*. 2008; 36:1634–1644. [PubMed: 18250085]
- Hait NC, Oskeritzian CA, Paugh SW, Milstien S, Spiegel S. Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases. *Biochim Biophys Acta*. 2006; 1758:2016–2026. [PubMed: 16996023]

- Hait NC, Allegood J, Maceyka M, Strub GM, Harikumar KB, Singh SK, et al. Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. *Science*. 2009; 325:1254–1257. [PubMed: 19729656]
- Hannun YA, Loomis CR, Merrill AH, Bell RM. Sphingosine inhibition of protein kinase C activity and of phorbol dibutyrate binding in vitro and in human platelets. *J Biol Chem*. 1986; 261:12604–12609. [PubMed: 3462188]
- Igarashi N, Okada T, Hayashi S, Fujita T, Jahangeer S, Nakamura S. Sphingosine kinase 2 is a nuclear protein and inhibits DNA synthesis. *J Biol Chem*. 2003; 278:46832–46839. [PubMed: 12954646]
- Ivens AC, Peacock CS, Worthey EA, Murphy L, Aggarwal G, Berriman M, et al. The genome of the kinetoplastid parasite, *Leishmania major*. *Science*. 2005; 309:436–442. [PubMed: 16020728]
- Kapler GM, Coburn CM, Beverley SM. Stable transfection of the human parasite *Leishmania major* delineates a 30-kilobase region sufficient for extra-chromosomal replication and expression. *Mol Cell Biol*. 1990; 10:1084–1094. [PubMed: 2304458]
- Karliner JS. Sphingosine kinase regulation and cardioprotection. *Cardiovasc Res*. 2009; 82:184–192. [PubMed: 19017750]
- Kim S, Fyrst H, Saba J. Accumulation of phosphorylated sphingoid long chain bases results in cell growth inhibition in *Saccharomyces cerevisiae*. *Genetics*. 2000; 156:1519–1529. [PubMed: 11102354]
- Kohama T, Olivera A, Edsall L, Nagiec MM, Dickson R, Spiegel S. Molecular cloning and functional characterization of murine sphingosine kinase. *J Biol Chem*. 1998; 273:23722–23728. [PubMed: 9726979]
- Kolter T, Proia RL, Sandhoff K. Combinatorial ganglioside biosynthesis. *J Biol Chem*. 2002; 277:25859–25862. [PubMed: 12011101]
- Lanterman MM, Saba JD. Characterization of sphingosine kinase (SK) activity in *Saccharomyces cerevisiae* and isolation of SK-deficient mutants. *Biochem J*. 1998; 332(Pt 2):525–531. [PubMed: 9601083]
- Liu H, Sugiura M, Nava VE, Edsall LC, Kono K, Poulton S, et al. Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform. *J Biol Chem*. 2000; 275:19513–19520. [PubMed: 10751414]
- Liu H, Chakravarty D, Maceyka M, Milstien S, Spiegel S. Sphingosine kinases: a novel family of lipid kinases. *Prog Nucleic Acid Res Mol Biol*. 2002; 71:493–511. [PubMed: 12102559]
- Maceyka M, Payne SG, Milstien S, Spiegel S. Sphingosine kinase, sphingosine-1-phosphate, and apoptosis. *Biochim Biophys Acta*. 2002; 1585:193–201. [PubMed: 12531554]
- McNicol F, Muller M, Cloutier S, Boilard N, Rochette A, Dube M, Papadopolou B. Distinct 3'-untranslated region elements regulate stage-specific mRNA accumulation and translation in *Leishmania*. *J Biol Chem*. 2005; 280:35238–35246. [PubMed: 16115874]
- Madeira da Silva L, Owens KL, Murta SM, Beverley SM. Regulated expression of the *Leishmania major* surface virulence factor lipophosphoglycan using conditionally destabilized fusion proteins. *Proc Natl Acad Sci USA*. 2009; 106:7583–7588. [PubMed: 19383793]
- Mao C, Obeid LM. Ceramidases: regulators of cellular responses mediated by ceramide, sphingosine, and sphingosine-1-phosphate. *Biochim Biophys Acta*. 2008; 1781:424–434. [PubMed: 18619555]
- Merrill AH Jr, Sereni AM, Stevens VL, Hannun YA, Bell RM, Kinkade JM. Inhibition of phorbol ester-dependent differentiation of human promyelocytic leukemic (HL-60) cells by sphinganine and other long-chain bases. *J Biol Chem*. 1986; 261:12610–12615. [PubMed: 3462189]
- Merrill AH Jr, Hannun YA, Bell RM. Introduction: sphingolipids and their metabolites in cell regulation. *Adv Lipid Res*. 1993; 25:1–24. [PubMed: 8368146]
- Mizugishi K, Yamashita T, Olivera A, Miller GF, Spiegel S, Proia RL. Essential role for sphingosine kinases in neural and vascular development. *Mol Cell Biol*. 2005; 25:11113–11121. [PubMed: 16314531]
- Nagiec MM, Skrzypek M, Nagiec EE, Lester RL, Dickson RC. The LCB4 (YOR171c) and LCB5 (YLR260w) genes of *Saccharomyces* encode sphingoid long chain base kinases. *J Biol Chem*. 1998; 273:19437–19442. [PubMed: 9677363]
- Pillai AB, Xu W, Zhang O, Zhang K. Sphingolipid degradation in *Leishmania (Leishmania) amazonensis*. *PLoS Negl Trop Dis*. 2012; 6:e1944. [PubMed: 23285302]

- Pitman MR, Pitson SM. Inhibitors of the sphingosine kinase pathway as potential therapeutics. *Curr Cancer Drug Targets*. 2010; 10:354–367. [PubMed: 20370685]
- Pitson SM. Regulation of sphingosine kinase and sphingolipid signaling. *Trends Biochem Sci*. 2011; 36:97–107. [PubMed: 20870412]
- Pitson SM, Xia P, Leclercq TM, Moretti PA, Zebol JR, Lynn HE, et al. Phosphorylation-dependent trans-location of sphingosine kinase to the plasma membrane drives its oncogenic signalling. *J Exp Med*. 2005; 201:49–54. [PubMed: 15623571]
- Pyne S, Pyne NJ. Translational aspects of sphingosine 1-phosphate biology. *Trends Mol Med*. 2011; 17:463–472. [PubMed: 21514226]
- Racoosin EL, Beverley SM. *Leishmania major*: promastigotes induce expression of a subset of chemokine genes in murine macrophages. *Exp Parasitol*. 1997; 85:283–295. [PubMed: 9085925]
- Raje MR, Knott K, Kharel Y, Bissel P, Lynch KR, Santos WL. Design, synthesis and biological activity of sphingosine kinase 2 selective inhibitors. *Bioorg Med Chem*. 2012; 20:183–194. [PubMed: 22137932]
- Rosen H, Gonzalez-Cabrera PJ, Sanna MG, Brown S. Sphingosine 1-phosphate receptor signaling. *Annu Rev Biochem*. 2009; 78:743–768. [PubMed: 19231986]
- Sacks DL, Perkins PV. Development of infective stage *Leishmania* promastigotes within phlebotomine sand flies. *Am J Trop Med Hyg*. 1985; 34:456–459. [PubMed: 4039899]
- Sacks DL, Hieny S, Sher A. Identification of cell surface carbohydrate and antigenic changes between noninfective and infective developmental stages of *Leishmania major* promastigotes. *J Immunol*. 1985; 135:564–569. [PubMed: 2582050]
- Santos DO, Coutinho CE, Madeira MF, Bottino CG, Vieira RT, Nascimento SB, et al. Leishmaniasis treatment – a challenge that remains: a review. *Parasitol Res*. 2008; 103:1–10. [PubMed: 18389282]
- Shida D, Takabe K, Kapitonov D, Milstien S, Spiegel S. Targeting SphK1 as a new strategy against cancer. *Curr Drug Targets*. 2008; 9:662–673. [PubMed: 18691013]
- Siow DL, Anderson CD, Berdyshev EV, Skobeleva A, Natarajan V, Pitson SM, Wattenberg BW. Sphingosine kinase localization in the control of sphingolipid metabolism. *Adv Enzyme Regul*. 2011; 51:229–244. [PubMed: 21075134]
- Spath GF, Beverley SM. A lipophosphoglycan-independent method for isolation of infective *Leishmania* metacyclic promastigotes by density gradient centrifugation. *Exp Parasitol*. 2001; 99:97–103. [PubMed: 11748963]
- Spath GF, Garraway LA, Turco SJ, Beverley SM. The role(s) of lipophosphoglycan (LPG) in the establishment of *Leishmania major* infections in mammalian hosts. *Proc Natl Acad Sci USA*. 2003; 100:9536–9541. [PubMed: 12869694]
- Stahelin RV, Hwang JH, Kim JH, Park ZY, Johnson KR, Obeid LM, Cho W. The mechanism of membrane targeting of human sphingosine kinase 1. *J Biol Chem*. 2005; 280:43030–43038. [PubMed: 16243846]
- Strub GM, Maceyka M, Hait NC, Milstien S, Spiegel S. Extracellular and intracellular actions of sphingosine-1-phosphate. *Adv Exp Med Biol*. 2010; 688:141–155. [PubMed: 20919652]
- Strub GM, Paillard M, Liang J, Gomez L, Allegood JC, Hait NC, et al. Sphingosine-1-phosphate produced by sphingosine kinase 2 in mitochondria interacts with prohibitin 2 to regulate complex IV assembly and respiration. *FASEB J*. 2011; 25:600–612. [PubMed: 20959514]
- Titus RG, Marchand M, Boon T, Louis JA. A limiting dilution assay for quantifying *Leishmania major* in tissues of infected mice. *Parasite Immunol*. 1985; 7:545–555. [PubMed: 3877902]
- Titus RG, Muller I, Kimsey P, Cerny A, Behin R, Zinkernagel RM, Louis JA. Exacerbation of experimental murine cutaneous leishmaniasis with CD4+ *Leishmania major*-specific T cell lines or clones which secrete interferon-gamma and mediate parasite-specific delayed-type hypersensitivity. *Eur J Immunol*. 1991; 21:559–567. [PubMed: 1672641]
- Vaux DL, Korsmeyer SJ. Cell death in development. *Cell*. 1999; 96:245–254. [PubMed: 9988219]
- Xia P, Wang L, Moretti PA, Albanese N, Chai F, Pitson SM, et al. Sphingosine kinase interacts with TRAF2 and dissects tumor necrosis factor-alpha signaling. *J Biol Chem*. 2002; 277:7996–8003. [PubMed: 11777919]

- Xu W, Xin L, Soong L, Zhang K. Sphingolipid degradation by *Leishmania major* is required for its resistance to acidic pH in the mammalian host. *Infect Immun*. 2011; 79:3377–3387. [PubMed: 21576322]
- Zhang K, Showalter M, Revollo J, Hsu FF, Turk J, Beverley SM. Sphingolipids are essential for differentiation but not growth in *Leishmania*. *EMBO J*. 2003; 22:6016–6026. [PubMed: 14609948]
- Zhang K, Barron T, Turco SJ, Beverley SM. The LPG1 gene family of *Leishmania major*. *Mol Biochem Parasitol*. 2004; 136:11–23. [PubMed: 15138063]
- Zhang K, Hsu FF, Scott DA, Docampo R, Turk J, Beverley SM. *Leishmania* salvage and remodelling of host sphingolipids in amastigote survival and acidocalcisome biogenesis. *Mol Microbiol*. 2005; 55:1566–1578. [PubMed: 15720561]
- Zhang K, Pompey JM, Hsu FF, Key P, Bandhuvula P, Saba JD, et al. Redirection of sphingolipid metabolism toward de novo synthesis of ethanolamine in *Leishmania*. *EMBO J*. 2007; 26:1094–1104. [PubMed: 17290222]
- Zhang L, Orban M, Lorenz M, Barocke V, Braun D, Urtz N, et al. A novel role of sphingosine 1-phosphate receptor S1pr1 in mouse thrombopoiesis. *J Exp Med*. 2012; 209:2165–2181. [PubMed: 23148237]
- Zhang O, Wilson MC, Xu W, Hsu FF, Turk J, Kuhlmann FM, et al. Degradation of host sphingomyelin is essential for *Leishmania* virulence. *PLoS Pathog*. 2009; 5:e1000692. [PubMed: 20011126]
- Zhang O, Xu W, Pillai A, Zhang K. Developmentally regulated sphingolipid degradation in *Leishmania major*. *PLoS ONE*. 2012; 7:e31059. [PubMed: 22299050]

Fig. 1. *Ska* encodes a functional SK in *L. major*

A–C. *In vitro* SK activity assay using *Leishmania* lysates. Promastigote lysates were incubated with NBD-Sph (A) or NBD-DHS (B) and lipid extraction was performed as described in *Experimental procedures*. Both the aqueous phase (top) and the organic phase were resolved by TLC (bottom). Positive control (+): 0.1 unit of purified human SK2; negative control (–): boiled WT lysate. These assays were repeated three times and results were quantified as $\mu\text{mol}/(\mu\text{g} \times \text{h})^{-1}$ and summarized in C (error bars represent standard deviations).

D. Metabolism of serine in *L major*. Early log phase promastigotes were labelled with [3-³H]-serine for 48 h and total lipids were extracted and resolved by TLC as previously described (Zhang *et al.*, 2003). O: origin of migration; F: solvent front.

Fig. 2. Cytoplasmic localization of the SKA protein. WT/ + GFP-SKa promastigotes (A–D) or WT/ + GFP-SKa-infected MΦs (E–I) were permeabilized and subjected to immunofluorescence microscopy. (A and E) Differential interference contrast images; (B and F) DNA staining with Hoechst 33242; (C and G) rabbit anti-GFP polyclonal antibody labelling followed by incubation with a Texas red-conjugated goat anti-rabbit IgG antibody; (D) GFP fluorescence; (H) overlay of F and G; (I) enlarged image of the framed area in H.

Fig. 3.

Loss of SKa leads to catastrophic defects in culture due to sphingoid base accumulation. (A and B) *Skar*⁻ mutants exhibit severe growth defects in culture. Promastigotes were inoculated at 1.0×10^5 cells ml⁻¹ and incubated at 27°C. Culture densities (A) and percentages of dead cells (B) were monitored daily. (C and D) Rescue of *Skar*⁻ mutants by MYR + EtN. *Skar*⁻ promastigotes were inoculated at 1.0×10^5 cells ml⁻¹ in the presence of EtN (200 μM), MYR (1 μM) or EtN + MYR (200 and 1 μM respectively) and incubated at 27°C. Culture densities (C) and percentages of dead cells (D) were monitored daily. These experiments were repeated 4–5 times and error bars represent standard deviations.

Fig. 4. *Ska*⁻ mutants supplemented with MYR and EtN show normal metacyclogenesis

A. Percentages of metacyclics were determined daily from stationary phase cultures of WT, *ska*⁻ (supplemented with 1 μ M of MYR only or 1 μ M of MYR + 200 μ M of EtN), *ska*⁻/+SKa, and *ska*⁻::HA-SKa using the density centrifugation method. Experiments were performed in triplicates and error bars represent standard deviations.

B. Representative differential interference contrast images of cells from day 3 stationary phase cultures.

Fig. 5.

Ska⁻ mutants are hypersensitive to stress conditions. (A and B) Promastigotes were cultured under regular condition (27°C, pH 7.4) to stationary phase before stress treatments. In A, parasites were transferred to 37°C, 33°C, or remained at 27°C. In B, half of the parasites were transferred to an acidic medium (pH 5.0) while the other half remained in regular medium (pH 7.4) for 72 h at 27°C. (C and D) Stationary phase promastigotes were challenged with various concentrations of SNAP (C) or hydrogen peroxide (D). In all experiments, *ska*⁻ promastigotes were complemented with 1 μM of MYR + 200 μM of EtN; percentages of cell death were determined at 24 h (A), 48 h (C and D), or 72 h (B) post treatments; and error bars indicate standard deviations from three independent repeats.

Fig. 6. *Ska*⁻ mutants supplemented with MYR and EtN survive well in MΦs *in vitro*. (A and B) Stationary phase promastigotes were used to infect bone-marrow derived MΦs (from BALB/c mice) as described in *Experimental procedures*. Percentage of infected MΦs (A) and the number of parasites in 100 MΦs (B) were recorded at 2, 24, 48 and 72 h post infection. As a control, WT promastigotes were also used to infect activated MΦs (pre-stimulated with 100 ng ml⁻¹ of LPS and 100 ng ml⁻¹ of IFN-γ). Error bars represent standard deviations.

Fig. 7.

Ska⁻ and *ska*⁻/+ *SKa* parasites fail to cause pathology in BALB/c mice while the chromosomal knockin (*ska*⁻::*HA-SKa*) is fully virulent. BALB/c mice were infected in the footpads with stationary phase promastigotes (1.0×10^6 cells per mouse, 5 mice per group). A. Lesion sizes of infected footpads were measured weekly with a caliper. B. Parasite numbers in the infected footpads were determined at 6 or 20 weeks post infection (w P.I.) by limiting dilution assay.

Table 1

Abundance of plasmenylethanolamine or PLE ($\times 10^7$ molecules per cell).

	WT	<i>ska</i> ⁻	<i>ska</i> ⁻ / <i>SKa</i>
PLE (early-log)	7.2 $\pm$ 0.4	5.0 $\pm$ 0.5	6.5 $\pm$ 1.8
PLE (mid-log)	6.3 $\pm$ 3.0	4.6 $\pm$ 2.0	6.8 $\pm$ 4.6

Abundance of PLE in early log phase ($1-2 \times 10^6$ cells ml⁻¹) or mid-log phase ($4-6 \times 10^6$ cells ml⁻¹) promastigotes were determined by semiquantitative mass spectrometry. Average values from two experiments are summarized with standard deviations.